FIGURE

Fig. 6

ID

ZDB-FIG-250609-105

Publication

Kuo et al., 2025 - The histamine pathway is a target to treat hepatic experimental erythropoietic protoporphyria

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

The role of the histamine pathway in porphyrin-stressed PMHs. Primary mouse hepatocytes (PMHs) were challenged with ALA + DFO that results in porphyrin accumulation, then treated with histamine (HT), CCZ, or other histamine blockers for 12 hours. (A) PMHs were treated with HT, the H1-blocker fexofenadine (FXF), and the H2-blockers cimetidine (CMT) and ranitidine (RNT) at the indicated doses. Intracellular and culture medium PP-IX levels following the treatments are shown. (B) CCZ and CMT were tested individually at 10 μM. Intracellular and medium PP-IX levels were measured in the absence of histamine. (C) CCZ and CMT were tested individually at 10 μM by treating primary mouse hepatocyte cultures. Intracellular and culture medium PP-IX levels in the presence or absence of histamine with levels relative to the condition without histamine. Data are shown as mean ± SD (n ≥3 experiments). Statistical analysis was performed by 1-way ANOVA test, ∗∗∗P < .001; ∗∗P < .01; ∗P < .05.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Mol Gastroenterol Hepatol